Latest / Community Health Media
Dr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib
The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM Conversations, Dr. Ruta Rao and Dr. Azadeh Nasrazadani discuss how the detection of PIK3CA, AKT, and PTEN mutations is redefining the role of capivasertib.
The clinicians differentiate the clinical application of capivasertib from other targeted agents like alpelisib and inavolisib, exploring how mechanistic differences and biomarker profiles influence patient selection. A central focus is placed on mastering the safety profile of these agents…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.